<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37190090</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>18</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Biofluid Biomarkers in the Prognosis of Amyotrophic Lateral Sclerosis: Recent Developments and Therapeutic Applications.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1180</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12081180</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis is a neurodegenerative disease characterized by the degeneration of motor neurons for which effective therapies are lacking. One of the most explored areas of research in ALS is the discovery and validation of biomarkers that can be applied to clinical practice and incorporated into the development of innovative therapies. The study of biomarkers requires an adequate theoretical and operational framework, highlighting the "fit-for-purpose" concept and distinguishing different types of biomarkers based on common terminology. In this review, we aim to discuss the current status of fluid-based prognostic and predictive biomarkers in ALS, with particular emphasis on those that are the most promising ones for clinical trial design and routine clinical practice. Neurofilaments in cerebrospinal fluid and blood are the main prognostic and pharmacodynamic biomarkers. Furthermore, several candidates exist covering various pathological aspects of the disease, such as immune, metabolic and muscle damage markers. Urine has been studied less often and should be explored for its possible advantages. New advances in the knowledge of cryptic exons introduce the possibility of discovering new biomarkers. Collaborative efforts, prospective studies and standardized procedures are needed to validate candidate biomarkers. A combined biomarkers panel can provide a more detailed disease status.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanchez-Tejerina</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5624-638X</Identifier><AffiliationInfo><Affiliation>Neuromuscular Diseases Unit, Neurology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peripheral Nervous System Group, Vall d'Hebron Research Institut (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Aut&#xf3;noma de Barcelona, 08035 Barcelon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llaurado</LastName><ForeName>Arnau</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4655-6157</Identifier><AffiliationInfo><Affiliation>Neuromuscular Diseases Unit, Neurology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peripheral Nervous System Group, Vall d'Hebron Research Institut (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotoca</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Unit, Neurology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peripheral Nervous System Group, Vall d'Hebron Research Institut (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez-Diego</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Unit, Neurology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peripheral Nervous System Group, Vall d'Hebron Research Institut (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal Taboada</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-5667-4133</Identifier><AffiliationInfo><Affiliation>Peripheral Nervous System Group, Vall d'Hebron Research Institut (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Aut&#xf3;noma de Barcelona, 08035 Barcelon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvado</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Unit, Neurology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peripheral Nervous System Group, Vall d'Hebron Research Institut (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juntas-Morales</LastName><ForeName>Raul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Unit, Neurology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peripheral Nervous System Group, Vall d'Hebron Research Institut (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Aut&#xf3;noma de Barcelona, 08035 Barcelon, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">neurofilament light (NfL) protein</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">pharmacodynamic biomarker</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>R.J.-M. and J.M.V.T. has received research grants from &#x201c;Instituto de Salud Carlos III&#x201d; and European Regional Development Fund: &#x201c;A way to make Europe&#x201c;. R.J.-M. was involved as site principal investigator for the following clinical trial sponsors: Orphazyme, PTC Therapeutics, Sanofi, Apellis Pharmaceuticals, Transposon Therapeutics, Corcept Therapeutics and Alexion. The other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37190090</ArticleId><ArticleId IdType="pmc">PMC10136823</ArticleId><ArticleId IdType="doi">10.3390/cells12081180</ArticleId><ArticleId IdType="pii">cells12081180</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primer. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E., Fang F. Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr. Opin. Neurol. 2019;32:771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H.-J., Debray T.P.A., Visser A.E., van Eijk R.P.A., Rooney J.P.K., Calvo A., Martin S., McDermott C.J., Thompson A.G., Pinto S., et al. Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman S.A., Hardiman O., Al-Chalabi A., Chi&#xf3; A., Savelieff M.G., Kiernan M.C., Feldman E.L. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21:465&#x2013;479. doi: 10.1016/S1474-4422(21)00414-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00414-2</ArticleId><ArticleId IdType="pmc">PMC9513754</ArticleId><ArticleId IdType="pubmed">35334234</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Vucic S., Talbot K., McDermott C.J., Hardiman O., Shefner J.M., Al-Chalabi A., Huynh W., Cudkowicz M., Talman P., et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2020;17:104&#x2013;118. doi: 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead R.J., Shan N., Reiser H.J., Marshall F., Shaw P.J. Amyotrophic lateral sclerosis: A neurodegenerative disorder poised for successful therapeutic translation. Nat. Rev. Drug Discov. 2022;22:185&#x2013;212. doi: 10.1038/s41573-022-00612-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00612-2</ArticleId><ArticleId IdType="pmc">PMC9768794</ArticleId><ArticleId IdType="pubmed">36543887</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg L.H., Sorenson E., Gronseth G., Macklin E.A., Andrews J., Baloh R.H., Benatar M., Berry J.D., Chio A., Corcia P., et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610&#x2013;e1623. doi: 10.1212/WNL.0000000000007242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk R.P.A., Kliest T., McDermott C.J., Roes K.C.B., Van Damme P., Chio A., Weber M., Ingre C., Corcia P., Povedano M., et al. TRICALS: Creating a highway toward a cure. Amyotroph. Lateral Scler. Front. Degener. 2020;21:496&#x2013;501. doi: 10.1080/21678421.2020.1788092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1788092</ArticleId><ArticleId IdType="pubmed">32643415</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomarkers Definitions Working Group. Atkinson A.J., Jr., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Hoth D.F., Oates J.A., Peck C.C., Spilker B.A., et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001;69:89&#x2013;95. doi: 10.1067/mcp.2001.113989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mcp.2001.113989</ArticleId><ArticleId IdType="pubmed">11240971</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA-NIH Biomarker Working Group . BEST (Biomarkers, EndpointS, and Other Tools) Resource. Food and Drug Administration; Silver Spring, MD, USA: 2016.</Citation><ArticleIdList><ArticleId IdType="pubmed">27010052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturmey E., Malaspina A. Blood biomarkers in ALS: Challenges, applications and novel frontiers. Acta Neurol. Scand. 2022;146:375&#x2013;388. doi: 10.1111/ane.13698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13698</ArticleId><ArticleId IdType="pmc">PMC9828487</ArticleId><ArticleId IdType="pubmed">36156207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.K., Cleveland D.W. Neuronal Intermediate Filaments. Annu. Rev. Neurosci. 1996;19:187&#x2013;217. doi: 10.1146/annurev.ne.19.030196.001155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.ne.19.030196.001155</ArticleId><ArticleId IdType="pubmed">8833441</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs E., Cleveland D.W. A Structural Scaffolding of Intermediate Filaments in Health and Disease. Science. 1998;279:514&#x2013;519. doi: 10.1126/science.279.5350.514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.279.5350.514</ArticleId><ArticleId IdType="pubmed">9438837</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren L.E., Karlsson J.-E., Karlsson J.-O., Persson L.I., Wikkels&#xf8; C. Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF. J. Neurochem. 2002;67:2013&#x2013;2018. doi: 10.1046/j.1471-4159.1996.67052013.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1996.67052013.x</ArticleId><ArticleId IdType="pubmed">8863508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambertsen K.L., Soares C.B., Gaist D., Nielsen H.H. Neurofilaments: The C-Reactive Protein of Neurology. Brain Sci. 2020;10:56. doi: 10.3390/brainsci10010056.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10010056</ArticleId><ArticleId IdType="pmc">PMC7016784</ArticleId><ArticleId IdType="pubmed">31963750</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M., Teunissen C.E., Otto M., Piehl F., Sormani M.P., Gattringer T., Barro C., Kappos L., Comabella M., Fazekas F., et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 2018;14:577&#x2013;589. doi: 10.1038/s41582-018-0058-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Zhang L., Wang L., Granit V., Statland J., Barohn R., Swenson A., Ravits J., Jackson C., Burns T.M., et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59&#x2013;e69. doi: 10.1212/WNL.0000000000009559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchiano V., Mastrangelo A., Zenesini C., Masullo M., Quadalti C., Avoni P., Polischi B., Cherici A., Capellari S., Salvi F., et al. Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study. Front. Aging Neurosci. 2021;13:753242. doi: 10.3389/fnagi.2021.753242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.753242</ArticleId><ArticleId IdType="pmc">PMC8569186</ArticleId><ArticleId IdType="pubmed">34744694</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Qin X., Chang X., Wang H., Guo J., Zhang W. Neurofilament markers in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J. Cell. Mol. Med. 2022;26:583&#x2013;587. doi: 10.1111/jcmm.17100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.17100</ArticleId><ArticleId IdType="pmc">PMC8743649</ArticleId><ArticleId IdType="pubmed">34866307</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Huss A., Mayer B., Grehl T., Grosskreutz J., Borck G., Kuhle J., Lul&#xe9; D., Meyer T., Oeckl P., et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotroph. Lateral Scler. Front. Degener. 2017;18:112&#x2013;119. doi: 10.1080/21678421.2016.1241279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1241279</ArticleId><ArticleId IdType="pubmed">27819158</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone Y.M., Domi T., Agosta F., Pozzi L., Schito P., Fazio R., Del Carro U., Barbieri A., Comola M., Leocani L., et al. Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. J. Neurol. 2020;267:2272&#x2013;2280. doi: 10.1007/s00415-020-09838-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09838-9</ArticleId><ArticleId IdType="pmc">PMC7166001</ArticleId><ArticleId IdType="pubmed">32306171</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Verber N., Bobeva Y., Lombardi V., Shepheard S.R., Yildiz O., Feneberg E., Farrimond L., Dharmadasa T., et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 2022;4:fcac029. doi: 10.1093/braincomms/fcac029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac029</ArticleId><ArticleId IdType="pmc">PMC8870425</ArticleId><ArticleId IdType="pubmed">35224491</ArticleId></ArticleIdList></Reference><Reference><Citation>Su W.-M., Cheng Y.-F., Jiang Z., Duan Q.-Q., Yang T.-M., Shang H.-F., Chen Y.-P. Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis. eBioMedicine. 2021;74:103732. doi: 10.1016/j.ebiom.2021.103732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103732</ArticleId><ArticleId IdType="pmc">PMC8646173</ArticleId><ArticleId IdType="pubmed">34864363</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Turner M.R. Neurofilament light chain in drug development for amyotrophic lateral sclerosis: A critical appraisal. Brain. 2022:awac394. doi: 10.1093/brain/awac394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac394</ArticleId><ArticleId IdType="pubmed">36310538</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P., Oeckl P., Huss A., M&#xfc;ller K., Volk A.E., Kuhle J., Knehr A., Andersen P.M., Prudlo J., Steinacker P., et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis: Biomarkers in ALS. Ann. Neurol. 2016;79:152&#x2013;158. doi: 10.1002/ana.24552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24552</ArticleId><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Lombardi V., Malaspina A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion: Neurofilament Light in Presymptomatic ALS. Ann. Neurol. 2018;84:130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Lombardi V., Jeromin A., Bowser R., Andersen P.M., Malaspina A. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph. Lateral Scler. Front. Degener. 2019;20:538&#x2013;548. doi: 10.1080/21678421.2019.1646769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Bucelli R.C., Andrews J.A., Otto M., Farahany N.A., Harrington E.A., Chen W., Mitchell A.A., et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: The ATLAS Study. Neurotherapeutics. 2022;19:1248&#x2013;1258. doi: 10.1007/s13311-022-01237-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01237-4</ArticleId><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.-H., Macdonald-Wallis C., Gray E., Pearce N., Petzold A., Norgren N., Giovannoni G., Fratta P., Sidle K., Fish M., et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2013;2257. doi: 10.1212/WNL.0000000000001642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Thouvenot E., Demattei C., Lehmann S., Maceski-Maleska A., Hirtz C., Juntas-Morales R., Pageot N., Esselin F., Alphand&#xe9;ry S., Vincent T., et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur. J. Neurol. 2020;27:251&#x2013;257. doi: 10.1111/ene.14063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14063</ArticleId><ArticleId IdType="pubmed">31437330</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Cudkowicz M.E., Genge A., Shaw P.J., Sobue G., Bucelli R.C., Chi&#xf2; A., Van Damme P., Ludolph A.C., Glass J.D., et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P., Miller T., Cudkowicz M., Genge A., Sobue G., Nestorov I., Graham D.I., Fanning L., Fradette S., McNeill M. Tofersen in adults with SOD1-ALS: Phase 3 VALOR trial and open-label extension results. J. Neurol. Neurosurg. Psychiatry. 2022;93:e2.208. doi: 10.1136/jnnp-2022-abn2.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2022-abn2.6</ArticleId></ArticleIdList></Reference><Reference><Citation>Darras B.T., Crawford T.O., Finkel R.S., Mercuri E., De Vivo D.C., Oskoui M., Tizzano E.F., Ryan M.M., Muntoni F., Zhao G., et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann. Clin. Transl. Neurol. 2019;6:932&#x2013;944. doi: 10.1002/acn3.779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.779</ArticleId><ArticleId IdType="pmc">PMC6530526</ArticleId><ArticleId IdType="pubmed">31139691</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina A., Puentes F., Amor S. Disease origin and progression in amyotrophic lateral sclerosis: An immunology perspective. Int. Immunol. 2015;27:117&#x2013;129. doi: 10.1093/intimm/dxu099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxu099</ArticleId><ArticleId IdType="pubmed">25344935</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Appel S.H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats K.A., Borchelt D.R., Tansey M.G., Wymer J. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol. Neurodegener. 2022;17:11. doi: 10.1186/s13024-022-00515-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00515-1</ArticleId><ArticleId IdType="pmc">PMC8785449</ArticleId><ArticleId IdType="pubmed">35073950</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R., Zecca C., Piccininni M., Benmahamed S., Dell&#x2019;Abate M.T., Barulli M.R., Capozzo R., Battista P., Logroscino G. Plasma Inflammatory Cytokines Are Elevated in ALS. Front. Neurol. 2020;11:552295. doi: 10.3389/fneur.2020.552295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.552295</ArticleId><ArticleId IdType="pmc">PMC7691268</ArticleId><ArticleId IdType="pubmed">33281700</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos D., Moreau C., Kyheng M., Gar&#xe7;on G., Rolland A.S., Blasco H., Gel&#xe9; P., Timoth&#xe9;e Lenglet T., Veyrat-Durebex C., Corcia P., et al. A ferroptosis&#x2013;based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Sci. Rep. 2019;9:2918. doi: 10.1038/s41598-019-39739-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39739-5</ArticleId><ArticleId IdType="pmc">PMC6393674</ArticleId><ArticleId IdType="pubmed">30814647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C., Lizio A., Maestri E., Sansone V.A., Mora G., Miller R.G., Appel S.H., Chi&#xf2; A. Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2017;74:660. doi: 10.1001/jamaneurol.2016.6179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6179</ArticleId><ArticleId IdType="pmc">PMC5822215</ArticleId><ArticleId IdType="pubmed">28384752</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Carrero J.J., Zagai U., Evans M., Ingre C., Pawitan Y., Fang F. Blood biomarkers and prognosis of amyotrophic lateral sclerosis. Eur. J. Neurol. 2020;27:2125&#x2013;2133. doi: 10.1111/ene.14409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14409</ArticleId><ArticleId IdType="pubmed">32557963</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel G., Peter R.S., Rosenbohm A., Koenig W., Dupuis L., Rothenbacher D., Ludolph A.C. Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis&#x2014;Results from a population- based ALS registry in Germany. Sci. Rep. 2017;7:4374. doi: 10.1038/s41598-017-04706-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04706-5</ArticleId><ArticleId IdType="pmc">PMC5491500</ArticleId><ArticleId IdType="pubmed">28663573</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese A., Sharma A., Mishra P., Vijayalakshmi K., Harsha H., Sathyaprabha T.N., Bharath S.M., Nalini A., Alladi P., Raju T.R. Chitotriosidase&#x2014;A putative biomarker for sporadic amyotrophic lateral sclerosis. Clin. Proteomics. 2013;10:19. doi: 10.1186/1559-0275-10-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1559-0275-10-19</ArticleId><ArticleId IdType="pmc">PMC4220794</ArticleId><ArticleId IdType="pubmed">24295388</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Verde F., Fang L., Feneberg E., Oeckl P., Roeber S., Anderl-Straub S., Danek A., Diehl-Schmid J., Fassbender K., et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J. Neurol. Neurosurg. Psychiatry. 2018;89:239&#x2013;247. doi: 10.1136/jnnp-2017-317138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317138</ArticleId><ArticleId IdType="pubmed">29142138</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Bampton A., Raciborska D., Talbot K., Turner M.R. CSF chitinase proteins in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:1215&#x2013;1220. doi: 10.1136/jnnp-2019-320442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B., De Schaepdryver M., Dedeene L., Goossens J., Claeys K.G., Van Den Bosch L., Tournoy J., Van Damme P., Poesen K. Inflammatory markers in cerebrospinal fluid: Independent prognostic biomarkers in amyotrophic lateral sclerosis? J. Neurol. Neurosurg. Psychiatry. 2019;90:1338&#x2013;1346. doi: 10.1136/jnnp-2018-319586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., De Schaepdryver M., Floeter M.K., De Vocht J., Lamaire N., D&#x2019;Hondt A., Traynor B., Poesen K., Van Damme P. Prognostic relationship of neurofilaments, CHIT1, YKL-40 and MCP-1 in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2021;93:681&#x2013;682. doi: 10.1136/jnnp-2021-327877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-327877</ArticleId><ArticleId IdType="pmc">PMC9148980</ArticleId><ArticleId IdType="pubmed">34911782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson M.P., Staff N.P., Bornschlegl S., Butler G.W., Maas M.L., Kazamel M., Zubair A., Gastineau D.A., Windebank A.J., Dietz A.B. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS ONE. 2017;12:e0182002. doi: 10.1371/journal.pone.0182002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182002</ArticleId><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock B.J., Zhou T., Kashlan S.R., Little R.J., Goutman S.A., Feldman E.L. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurol. 2017;74:1446. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Henkel J.S., Zhao W., Wang J., Huang A., Wen S., Liao B., Appel S.H. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134:1293&#x2013;1314. doi: 10.1093/brain/awr074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr074</ArticleId><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J.S., Beers D.R., Wen S., Rivera A.L., Toennis K.M., Appel J.E., Zhao W., Moore D.H., Powell S.Z., Appel S.H. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013;5:64&#x2013;79. doi: 10.1002/emmm.201201544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean R.K., McKay F.C., Cretney E., Bye C.R., Perera N.D., Tomas D., Weston R.A., Scheller K.J., Djouma E., Menon P., et al. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. JAMA Neurol. 2018;75:681. doi: 10.1001/jamaneurol.2018.0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes F., Lombardi V., Lu C., Yildiz O., Fratta P., Isaacs A., Bobeva Y., Wuu J., ALS Biomarker Consortium. CReATe Consortium et al. Humoral response to neurofilaments and dipeptide repeats in ALS progression. Ann. Clin. Transl. Neurol. 2021;8:1831&#x2013;1844. doi: 10.1002/acn3.51428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51428</ArticleId><ArticleId IdType="pmc">PMC8419401</ArticleId><ArticleId IdType="pubmed">34318620</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Pradat P.-F., Ludolph A.C., Loeffler J.-P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D., Hammar N., Malmstr&#xf6;m H., Ingre C., Jungner I., Ye W., Fang F., Walldius G. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort: Blood Biomarkers of Energy Metabolism and ALS Risk. Ann. Neurol. 2017;81:718&#x2013;728. doi: 10.1002/ana.24936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24936</ArticleId><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C., Chen L., Zhan Y., Termorshuizen J., Yin L., Fang F. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology. 2020;94:e1835&#x2013;e1844. doi: 10.1212/WNL.0000000000009322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009322</ArticleId><ArticleId IdType="pmc">PMC7274849</ArticleId><ArticleId IdType="pubmed">32221024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K., Hirayama T., Takazawa T., Kawabe K., Iwasaki Y. Relationships between Disease Progression and Serum Levels of Lipid, Urate, Creatinine and Ferritin in Japanese Patients with Amyotrophic Lateral Sclerosis: A Cross-Sectional Study. Intern. Med. 2012;51:1501&#x2013;1508. doi: 10.2169/internalmedicine.51.7465.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.51.7465</ArticleId><ArticleId IdType="pubmed">22728481</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Calvo A., Ilardi A., Cavallo E., Moglia C., Mutani R., Palmo A., Galletti R., Marinou K., Papetti L., et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73:1681&#x2013;1685. doi: 10.1212/WNL.0b013e3181c1df1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Deng J., Jaffa M., Cudkowicz M.E., Wills A.-M. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis: Body Mass Index Predicts Survival in ALS. Muscle Nerve. 2011;44:20&#x2013;24. doi: 10.1002/mus.22114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22114</ArticleId><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>van Mantgem M.R.J., van Rheenen W., Hackeng A.V., van Es M.A., Veldink J.H., van den Berg L.H., van Eijk R.P.A. Association Between Serum Lipids and Survival in Patients With Amyotrophic Lateral Sclerosis: A Meta-analysis and Population-Based Study. Neurology. 2022;100:e1062&#x2013;e1071. doi: 10.1212/WNL.0000000000201657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000201657</ArticleId><ArticleId IdType="pmc">PMC9990853</ArticleId><ArticleId IdType="pubmed">36460467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol J., Jov&#xe9; M., Povedano M., Sproviero W., Dom&#xed;nguez R., Pi&#xf1;ol-Ripoll G., Romero-Guevara R., Hye A., Al-Chalabi A., Torres P., et al. Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression. Brain Commun. 2021;3:fcab143. doi: 10.1093/braincomms/fcab143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab143</ArticleId><ArticleId IdType="pmc">PMC8361390</ArticleId><ArticleId IdType="pubmed">34396104</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Veyrat-Durebex C., Bocca C., Patin F., Vourc&#x2019;h P., Kouassi Nzoughet J., Lenaers G., Andres C.R., Simard G., Corcia P., et al. Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Sci. Rep. 2017;7:17652. doi: 10.1038/s41598-017-17389-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17389-9</ArticleId><ArticleId IdType="pmc">PMC5732162</ArticleId><ArticleId IdType="pubmed">29247199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerskiatiphanich T., Marallag J., Lee J. Glucose metabolism in amyotrophic lateral sclerosis: It is bitter-sweet. Neural Regen. Res. 2022;17:1975. doi: 10.4103/1673-5374.335154.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.335154</ArticleId><ArticleId IdType="pmc">PMC8848616</ArticleId><ArticleId IdType="pubmed">35142682</ArticleId></ArticleIdList></Reference><Reference><Citation>He J., Fu J., Zhao W., Ren C., Liu P., Chen L., Li D., Tang L., Zhou L., Zhang Y., et al. Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis. J. Neurol. 2022;269:1447&#x2013;1455. doi: 10.1007/s00415-021-10716-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10716-1</ArticleId><ArticleId IdType="pubmed">34274994</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn F.J., Ioannides Z.A., van Eijk R.P.A., Heggie S., Thorpe K.A., Ceslis A., Heshmat S., Henders A.K., Wray N.R., van den Berg L.H., et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J. Neurol. Neurosurg. Psychiatry. 2018;89:1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q.-Q., Chen Y., Cao B., Ou R.W., Zhang L., Hou Y., Gao X., Shang H. Blood hemoglobin A1c levels and amyotrophic lateral sclerosis survival. Mol. Neurodegener. 2017;12:69. doi: 10.1186/s13024-017-0211-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0211-y</ArticleId><ArticleId IdType="pmc">PMC5609007</ArticleId><ArticleId IdType="pubmed">28934974</ArticleId></ArticleIdList></Reference><Reference><Citation>Petillon C., Hergesheimer R., Puy H., Corcia P., Vourc&#x2019;h P., Andres C., Karim Z., Blasco H. The Relevancy of Data Regarding the Metabolism of Iron to Our Understanding of Deregulated Mechanisms in ALS.; Hypotheses and Pitfalls. Front. Neurosci. 2019;12:1031. doi: 10.3389/fnins.2018.01031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.01031</ArticleId><ArticleId IdType="pmc">PMC6341213</ArticleId><ArticleId IdType="pubmed">30697143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Li C., Chen X., Li S., Shang H. Abnormal Serum Iron-Status Indicator Changes in Amyotrophic Lateral Sclerosis (ALS) Patients: A Meta-Analysis. Front. Neurol. 2020;11:380. doi: 10.3389/fneur.2020.00380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00380</ArticleId><ArticleId IdType="pmc">PMC7251146</ArticleId><ArticleId IdType="pubmed">32508736</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., Chen Y., Shang H. Aberrations of biochemical indicators in amyotrophic lateral sclerosis: A systematic review and meta-analysis. Transl. Neurodegener. 2021;10:3. doi: 10.1186/s40035-020-00228-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-020-00228-9</ArticleId><ArticleId IdType="pmc">PMC7792103</ArticleId><ArticleId IdType="pubmed">33419478</ArticleId></ArticleIdList></Reference><Reference><Citation>Paydarnia P., Mayeli M., Shafie M., Agah E., Hasani S.A., Jazani M.R., Sarraf P. Alterations of the serum and CSF ferritin levels and the diagnosis and prognosis of amyotrophic lateral sclerosis. eNeurologicalSci. 2021;25:100379. doi: 10.1016/j.ensci.2021.100379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2021.100379</ArticleId><ArticleId IdType="pmc">PMC8626833</ArticleId><ArticleId IdType="pubmed">34869924</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Calvo A., Bovio G., Canosa A., Bertuzzo D., Galmozzi F., Cugnasco P., Clerico M., De Mercanti S., Bersano E., et al. Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and Creatinine: A Population-Based Study. JAMA Neurol. 2014;71:1134. doi: 10.1001/jamaneurol.2014.1129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1129</ArticleId><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Lee A., Nouwens A., Henderson R.D., McCombe P.A. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotroph. Lateral Scler. Front. Degener. 2018;19:362&#x2013;376. doi: 10.1080/21678421.2018.1433689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1433689</ArticleId><ArticleId IdType="pubmed">29384411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong M.-L., Tan P.F., Holbrook J.D. Predicting functional decline and survival in amyotrophic lateral sclerosis. PLoS ONE. 2017;12:e0174925. doi: 10.1371/journal.pone.0174925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0174925</ArticleId><ArticleId IdType="pmc">PMC5390993</ArticleId><ArticleId IdType="pubmed">28406915</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk R.P.A., Eijkemans M.J.C., Ferguson T.A., Nikolakopoulos S., Veldink J.H., van den Berg L.H. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry. 2018;89:156&#x2013;161. doi: 10.1136/jnnp-2017-317077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317077</ArticleId><ArticleId IdType="pmc">PMC5800333</ArticleId><ArticleId IdType="pubmed">29084868</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., Bejan-Angoulvant T., Patin F., Andres C.R., Vourc&#x2019;h P., Corcia P., Blasco H. Plasma creatinine and amyotrophic lateral sclerosis prognosis: A systematic review and meta-analysis. Amyotroph. Lateral Scler. Front. Degener. 2019;20:199&#x2013;206. doi: 10.1080/21678421.2019.1572192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1572192</ArticleId><ArticleId IdType="pubmed">30961401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H., Garofalo D.C., Santella R.M., Sorenson E.J., Oskarsson B., Fernandes J.A.M., Jr., Andrews H., Hupf J., Gilmore M., Heitzman D., et al. Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2020;21:263&#x2013;272. doi: 10.1080/21678421.2020.1746810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1746810</ArticleId><ArticleId IdType="pmc">PMC7373369</ArticleId><ArticleId IdType="pubmed">32276554</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q., Hu W., Xu L., Luo H., Wang N., Zhang Q. Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2021;8:448&#x2013;455. doi: 10.1002/acn3.51299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51299</ArticleId><ArticleId IdType="pmc">PMC7886033</ArticleId><ArticleId IdType="pubmed">33449454</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X.-P., Wei Q.-Q., Ou R.-W., Hou Y.-B., Zhang L.-Y., Yuan X.-Q., Yao Y.-Q., Jia D.-S., Zhang Q., Li W.-X., et al. Creatine kinase in the diagnosis and prognostic prediction of amyotrophic lateral sclerosis: A retrospective case-control study. Neural Regen. Res. 2021;16:591. doi: 10.4103/1673-5374.293159.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.293159</ArticleId><ArticleId IdType="pmc">PMC7996010</ArticleId><ArticleId IdType="pubmed">32985493</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccanti M., Pozzilli V., Cambieri C., Libonati L., Onesti E., Frasca V., Fiorini I., Petrucci A., Garibaldi M., Palma E., et al. Creatine Kinase and Progression Rate in Amyotrophic Lateral Sclerosis. Cells. 2020;9:1174. doi: 10.3390/cells9051174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051174</ArticleId><ArticleId IdType="pmc">PMC7291088</ArticleId><ArticleId IdType="pubmed">32397320</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq M.K., Lee E., Bradburn M., McDermott C.J., Shaw P.J. Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis. Eur. J. Neurol. 2016;23:1071&#x2013;1078. doi: 10.1111/ene.12995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12995</ArticleId><ArticleId IdType="pubmed">27029589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H., Cui L., Guan Y., Liu M., Li X., Shen D., Li D., Cui B., Fang J., Ding Q., et al. Correlation of Creatine Kinase Levels with Clinical Features and Survival in Amyotrophic Lateral Sclerosis. Front. Neurol. 2017;8:322. doi: 10.3389/fneur.2017.00322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00322</ArticleId><ArticleId IdType="pmc">PMC5494475</ArticleId><ArticleId IdType="pubmed">28717355</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Gomez S., Radermacher B., Tacik P., Mirandola S.R., Heneka M.T., Weydt P. Teaching an old dog new tricks: Serum troponin T as a biomarker in amyotrophic lateral sclerosis. Brain Commun. 2021;3:fcab274. doi: 10.1093/braincomms/fcab274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab274</ArticleId><ArticleId IdType="pmc">PMC8728713</ArticleId><ArticleId IdType="pubmed">34993474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kl&#xe4;ppe U., Chamoun S., Shen Q., Finn A., Evertsson B., Zetterberg H., Blennow K., Press R., Samuelsson K., M&#xe5;nberg A., et al. Cardiac troponin T is elevated and increases longitudinally in ALS patients. Amyotroph. Lateral Scler. Front. Degener. 2022;23:58&#x2013;65. doi: 10.1080/21678421.2021.1939384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1939384</ArticleId><ArticleId IdType="pubmed">34151677</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah P., Cho S.K., Thulstrup P.W., Bjerrum M.J., Lee P.H., Kang J.-H., Bhang Y.-J., Yang S.W. MicroRNA Biomarkers in Neurodegenerative Diseases and Emerging Nano-Sensors Technology. J. Mov. Disord. 2017;10:18&#x2013;28. doi: 10.14802/jmd.16037.</Citation><ArticleIdList><ArticleId IdType="doi">10.14802/jmd.16037</ArticleId><ArticleId IdType="pmc">PMC5288660</ArticleId><ArticleId IdType="pubmed">28122423</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci C., Marzocchi C., Battistini S. MicroRNAs as Biomarkers in Amyotrophic Lateral Sclerosis. Cells. 2018;7:219. doi: 10.3390/cells7110219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells7110219</ArticleId><ArticleId IdType="pmc">PMC6262636</ArticleId><ArticleId IdType="pubmed">30463376</ArticleId></ArticleIdList></Reference><Reference><Citation>Panio A., Cava C., D&#x2019;Antona S., Bertoli G., Porro D. Diagnostic Circulating miRNAs in Sporadic Amyotrophic Lateral Sclerosis. Front. Med. 2022;9:861960. doi: 10.3389/fmed.2022.861960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.861960</ArticleId><ArticleId IdType="pmc">PMC9121628</ArticleId><ArticleId IdType="pubmed">35602517</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen I., Yacovzada N.S., Yanowski E., Coenen-Stass A., Grosskreutz J., Lu C.-H., Greensmith L., Malaspina A., Fratta P., Hornstein E. Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nat. Neurosci. 2021;24:1534&#x2013;1541. doi: 10.1038/s41593-021-00936-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00936-z</ArticleId><ArticleId IdType="pubmed">34711961</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z., Zhang Y., Gendron T.F., Bauer P.O., Chew J., Yang W.-Y., Fostvedt E., Jansen-West K., Belzil V.V., Desaro P., et al. Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron. 2014;83:1043&#x2013;1050. doi: 10.1016/j.neuron.2014.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.07.041</ArticleId><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C., Oeckl P., Weishaupt J.H., Volk A.E., Diehl-Schmid J., Schroeter M.L., Lauer M., Kornhuber J., Levin J., Fassbender K., et al. Poly- GP in cerebrospinal fluid links C9orf72 -associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. EMBO Mol. Med. 2017;9:859&#x2013;868. doi: 10.15252/emmm.201607486.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607486</ArticleId><ArticleId IdType="pmc">PMC5494528</ArticleId><ArticleId IdType="pubmed">28408402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammack A.J., Atassi N., Hyman T., van den Berg L.H., Harms M., Baloh R.H., Brown R.H., van Es M.A., Veldink J.H., de Vries B.S., et al. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology. 2019;93:e1605&#x2013;e1617. doi: 10.1212/WNL.0000000000008359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008359</ArticleId><ArticleId IdType="pmc">PMC6946465</ArticleId><ArticleId IdType="pubmed">31578300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Chew J., Stankowski J.N., Hayes L.R., Zhang Y.-J., Prudencio M., Carlomagno Y., Daughrity L.M., Jansen-West K., Perkerson E.A., et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaai7866. doi: 10.1126/scitranslmed.aai7866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen  Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis; 2022.  [(accessed on 2 March 2023)].  Available online:  https://investors.biogen.com/news-releases/news-release-details/biogen-and-ionis-announce-topline-phase-1-study-results.</Citation></Reference><Reference><Citation>Forte G., Bocca B., Oggiano R., Clemente S., Asara Y., Sotgiu M.A., Farace C., Montella A., Fois A.G., Malaguarnera M., et al. Essential trace elements in amyotrophic lateral sclerosis (ALS): Results in a population of a risk area of Italy. Neurol. Sci. 2017;38:1609&#x2013;1615. doi: 10.1007/s10072-017-3018-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-3018-2</ArticleId><ArticleId IdType="pubmed">28601974</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocca B., Forte G., Oggiano R., Clemente S., Asara Y., Peruzzu A., Farace C., Pala S., Fois A.G., Pirina P., et al. Level of neurotoxic metals in amyotrophic lateral sclerosis: A population-based case&#x2013;control study. J. Neurol. Sci. 2015;359:11&#x2013;17. doi: 10.1016/j.jns.2015.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.10.023</ArticleId><ArticleId IdType="pubmed">26671079</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernfors P., Henschen A., Olson L., Persson H. Expression of nerve growth factor receptor mRNA is developmentally regulated and increased after axotomy in rat spinal cord motoneurons. Neuron. 1989;2:1605&#x2013;1613. doi: 10.1016/0896-6273(89)90049-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(89)90049-4</ArticleId><ArticleId IdType="pubmed">2560649</ArticleId></ArticleIdList></Reference><Reference><Citation>DiStefano P.S., Johnson E.M. Identification of a truncated form of the nerve growth factor receptor. Proc. Natl. Acad. Sci. USA. 1988;85:270&#x2013;274. doi: 10.1073/pnas.85.1.270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.1.270</ArticleId><ArticleId IdType="pmc">PMC279526</ArticleId><ArticleId IdType="pubmed">2829174</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeburger J.L., Tarras S., Natter H., Springer J.E. Spinal cord motoneurons express p75NGFR and p145trkB mRNA in amyotrophic lateral sclerosis. Brain Res. 1993;621:111&#x2013;115. doi: 10.1016/0006-8993(93)90304-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(93)90304-6</ArticleId><ArticleId IdType="pubmed">8221061</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard S.R., Chataway T., Schultz D.W., Rush R.A., Rogers M.-L. The Extracellular Domain of Neurotrophin Receptor p75 as a Candidate Biomarker for Amyotrophic Lateral Sclerosis. PLoS ONE. 2014;9:e87398. doi: 10.1371/journal.pone.0087398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0087398</ArticleId><ArticleId IdType="pmc">PMC3903651</ArticleId><ArticleId IdType="pubmed">24475283</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia R., Shepheard S., Jin J., Hu F., Zhao X., Xue L., Xiang L., Qi H., Qu Q., Guo F., et al. Urinary Extracellular Domain of Neurotrophin Receptor p75 as a Biomarker for Amyotrophic Lateral Sclerosis in a Chinese cohort. Sci. Rep. 2017;7:5127. doi: 10.1038/s41598-017-05430-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-05430-w</ArticleId><ArticleId IdType="pmc">PMC5506052</ArticleId><ArticleId IdType="pubmed">28698670</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard S.R., Wuu J., Cardoso M., Wiklendt L., Dinning P.G., Chataway T., Schultz D., Benatar M., Rogers M.-L. Urinary p75 ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137&#x2013;1143. doi: 10.1212/WNL.0000000000003741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi G., Shao S., Zhou J., Huang K., Bi F.-F. Urinary p75 ECD levels in patients with amyotrophic lateral sclerosis: A meta-analysis. Amyotroph. Lateral Scler. Front. Degener. 2022;23:438&#x2013;445. doi: 10.1080/21678421.2021.1990345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1990345</ArticleId><ArticleId IdType="pubmed">34726989</ArticleId></ArticleIdList></Reference><Reference><Citation>Molero-Luis M., Fern&#xe1;ndez-Ure&#xf1;a S., Jord&#xe1;n I., Serrano M., Ormaz&#xe1;bal A., Garcia-Cazorla &#xc0;., Artuch R. The Neopterin working group Cerebrospinal Fluid Neopterin Analysis in Neuropediatric Patients: Establishment of a New Cut Off-Value for the Identification of Inflammatory-Immune Mediated Processes. PLoS ONE. 2013;8:e83237. doi: 10.1371/journal.pone.0083237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0083237</ArticleId><ArticleId IdType="pmc">PMC3867431</ArticleId><ArticleId IdType="pubmed">24367586</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdowska A., Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J. Clin. Pharm. Ther. 2001;26:319&#x2013;329. doi: 10.1046/j.1365-2710.2001.00358.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2710.2001.00358.x</ArticleId><ArticleId IdType="pubmed">11679022</ArticleId></ArticleIdList></Reference><Reference><Citation>Molero-Luis M., Casas-Alba D., Orellana G., Ormazabal A., Sierra C., Oliva C., Valls A., Velasco J., Launes C., Cuadras D., et al. Cerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseases. Sci. Rep. 2020;10:18291. doi: 10.1038/s41598-020-75500-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-75500-z</ArticleId><ArticleId IdType="pmc">PMC7588460</ArticleId><ArticleId IdType="pubmed">33106568</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C., Lizio A., Gerardi F., Tarlarini C., Filippi M., Riva N., Tremolizzo L., Diamanti S., Dellanoce C.C., Mosca L., et al. Urinary neopterin, a new marker of the neuroinflammatory status in amyotrophic lateral sclerosis. J. Neurol. 2020;267:3609&#x2013;3616. doi: 10.1007/s00415-020-10047-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10047-7</ArticleId><ArticleId IdType="pubmed">32638112</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard S.R., Karnaros V., Benyamin B., Schultz D.W., Dubowsky M., Wuu J., Chataway T., Malaspina A., Benatar M., Rogers M. Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis. Eur. J. Neurol. 2022;29:990&#x2013;999. doi: 10.1111/ene.15237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15237</ArticleId><ArticleId IdType="pmc">PMC8901536</ArticleId><ArticleId IdType="pubmed">34967083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X.R., Prudencio M., Koike Y., Vatsavayai S.C., Kim G., Harbinski F., Briner A., Rodriguez C.M., Guo C., Akiyama T., et al. TDP-43 represses cryptic exon inclusion in the FTD&#x2013;ALS gene UNC13A. Nature. 2022;603:124&#x2013;130. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A.-L., Wilkins O.G., Keuss M.J., Hill S.E., Zanovello M., Lee W.C., Bampton A., Lee F.C.Y., Masino L., Qi Y.A., et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;137. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra F.P., van Vught P.W.J., van Rheenen W., Koppers M., Pasterkamp R.J., van Es M.A., Schelhaas H.J., de Visser M., Robberecht W., Van Damme P., et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol. Aging. 2012;33:630.e3&#x2013;630.e8. doi: 10.1016/j.neurobiolaging.2011.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.029</ArticleId><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Jiang H., Wang F., Li S., Wu C., Bao J., Zhu Y., Xu Z., Liu B., Ren H., et al. UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: A meta-analysis. Neurol. Sci. 2019;40:2293&#x2013;2302. doi: 10.1007/s10072-019-03951-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03951-y</ArticleId><ArticleId IdType="pubmed">31201598</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal-Taboada J.M., Lopez-Lopez A., Salvado M., Lorenzo L., Garcia C., Mahy N., Rodr&#xed;guez M.J., Gamez J. UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort. J. Neurol. 2015;262:2285&#x2013;2292. doi: 10.1007/s00415-015-7843-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7843-z</ArticleId><ArticleId IdType="pubmed">26162714</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk R.P.A., Jones A.R., Sproviero W., Shatunov A., Shaw P.J., Leigh P.N., Young C.A., Shaw C.E., Mora G., Mandrioli J., et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89:1915&#x2013;1922. doi: 10.1212/WNL.0000000000004606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004606</ArticleId><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Willemse S.W., Roes K.C.B., Van Damme P., Hardiman O., Ingre C., Povedano M., Wray N.R., Gijzen M., de Pagter M.S., Demaegd K.C., et al. Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: Protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial. Trials. 2022;23:978. doi: 10.1186/s13063-022-06906-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-022-06906-5</ArticleId><ArticleId IdType="pmc">PMC9721045</ArticleId><ArticleId IdType="pubmed">36471413</ArticleId></ArticleIdList></Reference><Reference><Citation>Krus K.L., Strickland A., Yamada Y., Devault L., Schmidt R.E., Bloom A.J., Milbrandt J., DiAntonio A. Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy. Cell Rep. 2022;39:111001. doi: 10.1016/j.celrep.2022.111001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111001</ArticleId><ArticleId IdType="pmc">PMC9327139</ArticleId><ArticleId IdType="pubmed">35767949</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden A.C., Kim H.-J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., Messing J., Kim H.J., Soriano A., Auburger G., et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Boylan K., Jeromin A., Rutkove S.B., Berry J., Atassi N., Bruijn L. ALS biomarkers for therapy development: State of the field and future directions: ALS Biomarkers. Muscle Nerve. 2016;53:169&#x2013;182. doi: 10.1002/mus.24979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24979</ArticleId><ArticleId IdType="pmc">PMC4718795</ArticleId><ArticleId IdType="pubmed">26574709</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar U.G., Milla V., Cynthia Stafford M.Y., Bjourson A.J., Duddy W., Duguez S.M.-R. A Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS. Front. Neurol. 2019;10:400. doi: 10.3389/fneur.2019.00400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00400</ArticleId><ArticleId IdType="pmc">PMC6527847</ArticleId><ArticleId IdType="pubmed">31139131</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>